Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc., a pioneering biopharmaceutical company based in the United States, focuses on developing innovative cannabinoid-based therapies for neuropsychiatric conditions. Founded in 2007, Zynerba has made significant strides in the industry, particularly with its transdermal delivery systems that enhance the bioavailability of cannabinoids. The company’s flagship products, including Zygel, are designed to treat conditions such as autism spectrum disorder and osteoarthritis, setting Zynerba apart with their unique formulation and delivery methods. With a strong commitment to research and development, Zynerba has positioned itself as a leader in the cannabinoid therapeutics market, achieving notable milestones in clinical trials and regulatory advancements. As it continues to expand its operational footprint, Zynerba Pharmaceuticals remains dedicated to improving patient outcomes through innovative solutions.
DitchCarbon Score
How does Zynerba Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zynerba Pharmaceuticals, Inc.'s score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zynerba Pharmaceuticals, Inc.'s reported carbon emissions
Zynerba Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. However, it is important to note that Zynerba Pharmaceuticals is a current subsidiary of Harmony Biosciences Holdings, Inc. This relationship may imply that any future emissions data or climate initiatives could be influenced by the parent company's strategies and commitments. As of now, there are no specific emissions figures or reduction initiatives reported from either Zynerba or its parent company. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate action. While Zynerba Pharmaceuticals has yet to disclose its own commitments, the industry trend towards transparency and accountability in carbon emissions may prompt future disclosures and initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zynerba Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
